Peter Lin MD, CCFP
Director, Primary Care Initiatives, Canadian Heart Research Centre, North York, OntarioDr. Peter Lin, a primary care physician, is the Director of Primary Care Initiatives at the Canadian Heart Research Centre and has two busy family medicine practices in Toronto. For 7 years, he served as the medical director at the University of Toronto Scarborough Health & Wellness Centre. In 2011, he received a teaching award from the College of Family Physicians of Canada.
Dr. Lin has worked with KDIGO (Kidney Disease│Improving Global Outcomes) in an effort to help enhance care for patients with chronic kidney disease. He has been a contributing author to the Canadian Diabetes Guidelines and has served on the editorial board of Pri-Med Institute, which provides education for physicians.
Dr. Lin maintains an active lecture schedule, reflecting his varied medical interests, continuing his focus on bridging the chasm between research and clinical practice.
Disclosures
- Consultant (continuing medical education programs): AstraZeneca; Boehringer Ingelheim; Bayer; Eli Lilly; Amgen; Janssen; Merck; Pfizer; Sanofi; Abbott; HLS Therapeutics
Recent Contributions to PracticeUpdate:
- Dexamethasone in Hospitalized Patients With COVID-19
- Azithromycin Use and Cardiovascular Mortality
- Statin Use and All-Cause and Cardiovascular Mortality in US Veterans ≥75 Years
- USPSTF Advises Annual Low-Dose CT Lung Screening for High-Risk Individuals
- Effect of Colchicine vs Standard Care on Cardiac and Inflammatory Biomarkers and Clinical Outcomes in Patients Hospitalized With COVID-19
- OPTIMISE: Reduced Antihypertensive Meds in Older Patients
- Variation in False-Negative Rate of RT-PCR–Based SARS-CoV-2 Tests by Time Since Exposure
- Triple Combination of Interferon Beta-1b, Lopinavir–Ritonavir, and Ribavirin in the Treatment of Patients Admitted to the Hospital With COVID-19
- Use of SGLT2 Inhibitors and Risk of Serious Renal Events
- SARS-Cov-2 Interaction With the Renin-Angiotensin System